Yes, Ativan (lorazepam) is problematic in Lewy body disease and should be avoided or used with extreme caution.
Benzodiazepines like Ativan are associated with accelerated functional decline in Lewy body dementia and should be deprescribed when possible. 1
Why This Is a Problem
The most recent high-quality evidence from a 5-year longitudinal cohort study demonstrates that benzodiazepine use in Lewy body dementia (LBD) is associated with faster functional decline, particularly when combined with antidepressants 1. This directly impacts quality of life and morbidity—your primary concerns.
Key Risks in Lewy Body Disease:
Functional Deterioration:
- Benzodiazepines alone cause greater functional decline in LBD patients 1
- The combination of benzodiazepines and antidepressants shows the worst outcomes 1
- This effect persists over years, not just acutely
Cognitive Impairment:
- Benzodiazepines worsen cognitive function in dementia 2
- They cause sedation, slowed comprehension, and delirium 2
- Patients with LBD are particularly vulnerable to anticholinergic and sedating effects
Falls and Injury:
- Marked as high-risk in older adults with dementia 2
- Causes unsafe mobility, motor skill impairment, and injurious falls 2
- LBD patients already have baseline motor impairment, compounding this risk
Paradoxical Worsening:
- One case report showed lorazepam combined with duloxetine induced visual hallucinations in prodromal DLB 3
- Reduced attentional control from benzodiazepines may worsen hallucinations 3
Clinical Guideline Recommendations
Deprescribing is strongly recommended 2:
- Benzodiazepines should be tapered and avoided if possible, especially for behavioral control in cognitive disease
- Consider cognitive behavioral therapy and non-pharmacological alternatives
- The EMPOWER taper technique is recommended for safe discontinuation 2
Important Caveats
One Exception: A single case report showed lorazepam improved catatonia in a DLB patient 4, but this is an extremely specific scenario (catatonia) and doesn't justify general use.
General FDA Warnings 5:
- Respiratory depression risk
- Excessive sedation with prolonged duration of action
- Patients over 50 have more profound and prolonged sedation
- Withdrawal syndromes with chronic use
What to Do Instead
For neuropsychiatric symptoms in LBD:
- Cholinesterase inhibitors (donepezil, rivastigmine) have level-1 evidence for managing hallucinations and cognitive symptoms 6
- Pimavanserin is FDA-approved for Parkinson's disease psychosis and shows promise in LBD 7
- Non-pharmacological interventions including cognitive rehabilitation and physical therapy 8
If Ativan is already prescribed: Initiate a taper plan immediately, considering the patient's clinical stability and using the EMPOWER technique 2. The functional decline is progressive with continued use 1.